A vaccine for hypertension

Journal of Hypertension

Volumn 25, Issue 1, 2007, Pages 41-46

  Ménard, Joël ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ALUMINUM HYDROXIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; LOSARTAN; MUMPS VACCINE; PEPTIDE DERIVATIVE; RAMIPRIL; SQUALENE; THIOMERCAPTOL; VACCINE;

AUTISM; BLOOD PRESSURE REGULATION; CHRONIC FATIGUE SYNDROME; DEVELOPING COUNTRY; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FIBROMYALGIA; HUMAN; HYPERTENSION; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPEATED DRUG DOSE; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; SURVIVAL; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 33845372028     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328012981b     Document Type: Editorial

References (77)

1. Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007; 25:63-72.
2. Krum H, Gilbert R. Novel therapies blocking the renin-angiotensin- aldosterone system in the management of hypertension and related disorders. J Hypertens 2007; 25:25-35.
3. Bumpus FM, Schwarz H, Page IH. Synthesis and properties of angiotonin. Circulation 1958; 17:664-667.
4. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977; 196:441-444.
5. Wong PC, Chiu AT, Price WA, Thoolen MJ, Carini DJ, Johnson AL, et al. Nonpeptide angiotensin II receptor antagonists I Pharmacological characterization of 2-n-butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid, sodium salt (S-8307). J Pharmacol Exp Ther 1988; 247:1-7.
6. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308:698-705.
7. Goldblatt H, Haas E, Lamfrom H. Antirenin in man and animals. Trans Assoc Am Physicians 1951; 64:122-125.
8. Wakerlin GE, Bird RB, Brennan BB, Frank MH, Kremen S, Kuperman I, Skom JH. Treatment and prophylaxis of experimental renal hypertension with renin. J Lab Clin Med 1953; 41:708-728.
9. Wakerlin GE. Antibodies to renin as proof the pathogenesis of sustained renal hypertension. Circulation 1958; 17:653-657.
10. Helmer M. Studies on renin antibodies. Circulation 1958; 17:648-652.
11. Schmid HE Jr. Grahamla Juxtaglomerular cell changes in dogs with antirenin titers. Circ Res 1962; 11:853-856.
12. Schmid HE Jr, Graham L, Brennan BB, Wakerlin GE. Renin concentration of normotensive and hypertensive dog kidney: its relation to serum antirenin titer. Circ Res 1962; 10:696-703.
13. Ganong WF, Lee TC, Vanbrunt EE, Biglieri EG. Aldosterone secretion in dogs immunized with hog renin. Endocrinology 1965; 76:1141-1149.
14. Louis WJ, Macdonald GJ, Renzini V, Boyd GW, Peart WS. Renal-clip hypertension in rabbits immunised against angiotensin II. Lancet 1970; 1:333-335.
15. Macdonald GJ, Louis WJ, Renzini V, Boyd GW, Peart WS. Renal-clip hypertension in rabbits immunized against angiotensin II. Circ Res 1970; 27:197-211.
16. Christleib AR, Hickler RB. Blood pressure response and antibody formation in spontaneously hypertensive rats and normal albino rats after immunization against angiotensin II. Endocrinology 1972; 91:1064-1070.
17. Eide I. Renovascular hypertension in rats immunized with angiotensin II. Circ Res 1972; 30:149-157.
18. Corvol P, Menard J. Renin purification and cloning. Hypertension 1991; 18:252-256.
19. Hofbauer KG, Menard J, Michel JB, Wood JM. Inhibition of renin in the primate Callithrix jacchus (common marmoset). Clin Exp Hypertens A 1983; 5:1237-1247.
20. Schnell CR, Wood JM. Measurement of blood pressure and heart rate by telemetry in conscious, unrestrained marmosets. Am J Physiol 1993; 264:H1509-H1516.
21. Michel JB, Guettier C, Philippe M, Galen FX, Corvol P, Menard J. Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci USA 1987; 84:4346-4350.
22. Michel JB, Sayah S, Guettier C, Nussberger J, Philippe M, Gonzalez MF, et al. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation 1990; 81:1899-1910.
23. Marsden PA. RNA interference as potential therapy - not so fast. N Engl J Med 2006; 355:953-954.
24. Gardiner SM, Auton TR, Downham MR, Sharp HL, Kemp PA, March JE, et al. Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. Br J Pharmacol 2000; 129:1178-1182.
25. Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR, Glover JF. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004; 107:167-173.
26. Downham MR, Auton TR, Rosul A, Sharp HL, Sjostrom L, Rushton A, et al. Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol 2003; 56:505-512.
27. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006; 114:838-854.
28. Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 2006; 114:855-860.
29. Castedo M, Pelletier L, Pasquier R, Guettier C, Huygen K, Michel JB, Druet P. Anti-renin T cells trigger normal B cells to produce anti-renin antibodies and normalize blood pressure in spontaneously hypertensive rats. Int Immunol 1993; 5:1569-1576.
30. Jegerlehner A, Tissot A, Lechner F, Sebbel P, Erdmann I, Kundig T, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002; 20:3104-3112.
31. Gomez RA, Norwood VF. Developmental consequences of the renin-angiotensin system. Am J Kidney Dis 1995; 26:409-431.
32. Corvol P, Schutz S, Gasc JM. Early expression of all components of the renin-angiotensin system in human development. Adv Nephrol Necker Hosp 1998; 28:195-212.
33. Gribouval O, Gonzales M, Neuhaus T, Aziza J, Bieth E, Laurent N, et al. Mutations in genes in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis. Nat Genet 2005; 37:964-968.
34. Menard J, Campbell DJ, Azizi M, Gonzales MF. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 1997; 96:3072-3078.
35. Griffiths CD, Morgan TO, Delbridge LM. Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high NaCl intake. J Hypertens 2001; 19:2087-2095.
36. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
37. Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists. Hypertension 1999; 33:850-855.
38. Hasler C, Nussberger J, Maillard M, Forclaz A, Brunner HR, Burnier M. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 2005; 78:501-507.
39. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Menard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92:825-834.
40. Bentley JP, Thacker PG. The influence of risk and monetary payment on the research participation decision making process. J Med Ethics 2004; 30:293-298.
41. Mandeville K. My life as a guinea pig. BMJ 2006; 332:735.
42. Shalala D. Protecting research subjects - what must be done. N Engl J Med 2000; 343:808-810.
43. Slater EE. IRB reform. N Engl J Med 2002; 346:1402-1404.
44. Slater EE. Today's FDA. N Engl J Med 2005; 352:293-297.
45. Steinbrook R. Wall Street and clinical trials. N Engl J Med 2005; 353:1091-1093.
46. Steinbrook R. Protecting research subjects - the crisis at Johns Hopkins. N Engl J Med 2002; 346:716-720.
47. Goodyear M. Learning from the TGN1412 trial. BMJ 2006; 332:677-678.
48. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-1028.
49. Blass JP. Immunologic treatment of Alzheimer's disease. N Engl J Med 1999; 341:1694-1695.
50. Bradbury J. First autopsy results from Alzheimer vaccine trial release. Lancet 2003; 361:1020.
51. Wood AJ, Darbyshire J. Injury to research volunteers - the clinical-research nightmare. N Engl J Med 2006; 354:1869-1871.
52. Michel JB. Renin-angiotensin vaccine: old story, new project 'efficacy versus safety'. Clin Sci (Lond) 2004; 107:145-147.
53. Ready T. Blood pressure vaccine shot down by safety concerns. Nat Med 2005; 11:1262.
54. Bachmann MF, Nussberger J, Tissot AC, Jennings GT. Reply to 'Blood pressure vaccine shot down by safety concerns'. Nat Med 2006; 12:270.
55. Ada G. Vaccines and vaccination. N Engl J Med 2001; 345:1042-1053.
56. Poland GA, Murray D, Bonilla-Guerrero R. New vaccine development. BMJ 2002; 324:1315-1319.
57. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116:1167-1173.
58. Verhage DF, Telgt DS, Bousema JT, Hermsen CC, van Gemert GJ, van der Meer JW, Sauerwein RW. Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J Med 2005; 63:52-58.
59. Houghton AN. On course for a cancer vaccine. Lancet 1995; 345:1384-1385.
60. Ahmad K. Tailored prostate cancer vaccine looks promising. Lancet 1999; 354:1533.
61. Glass RI, Bresee J, Jiang B, Parashar U, Yee E, Gentsch J. Rotavirus and rotavirus vaccines. Adv Exp Med Biol 2006; 582:45-54.
62. Hall WD. Will nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases? PLoS Med 2005; 2:E266.
63. Zhu F, Liao YH, Li LD, Cheng M, Wei F, Wei YM, Wang M. Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats. Cell Mol Immunol 2006; 3:107-114.
64. Bouhnik J, Galen FX, Menard J, Corvol P, Seyer R, Fehrentz JA, et al. Production and characterization of human renin antibodies with region-oriented synthetic peptides. J Biol Chem 1987; 262:2913-2918.
65. Dechend R, Homuth V, Wallukat G, Muller DN, Krause M, Dudenhausen J, et al. Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia. J Soc Gynecol Investig 2006; 13:79-86.
66. Chackerian B, Lenz P, Lowy DR, Schiller JT. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 2002; 169:6120-6126.
67. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351:2295-2301.
68. Dupont J, Altclas J, Lepetic A, Lombardo M, Vazquez V, Salgueira C, et al. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine. Vaccine 2006; Jul 12; [Epub ahead of print].
69. Classen JB, Classen DC. Public should be told that vaccines may have long term adverse effects. BMJ 1999; 318:193.
70. Clements CJ, McIntyre PB. When science is not enough - a risk/benefit profile of thiomersal-containing vaccines. Expert Opin Drug Saf 2006; 5:17-29.
71. Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 2006; 78:169-177.
72. Heller D. Ethical debate: vaccination against mumps, measles, and rubella: is there a case for deepening the debate? Validity of the evidence. BMJ 2001; 323:839-840.
73. Heller T. Ethical debate: vaccination against mumps, measles, and rubella: is there a case for deepening the debate? How safe is MMR vaccine? BMJ 2001; 323:838-839.
74. Pattison S. Ethical debate: vaccination against mumps, measles, and rubella: is there a case for deepening the debate? Dealing with uncertainty. BMJ 2001; 323:840.
75. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347:911-920.
76. Jover B, Michel JB, Dupont M, Corvol P, Mimran A. Adaptation to sodium restriction in renin-immunized spontaneously hypertensive and normotensive rats. Am J Physiol 1992; 262:H215-H219.
77. Lebron JA, Wolf JJ, Kaplanski CV, Ledwith BJ. Ensuring the quality, potency and safety of vaccines during preclinical development. Expert Rev Vaccines 2005; 4:855-866.